N-((1Z)-1-aza-2-(4-pyridyl)prop-1-enyl)(tert-butoxy)-carboxamide | 944882-27-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-((1Z)-1-aza-2-(4-pyridyl)prop-1-enyl)(tert-butoxy)-carboxamide
• 英文别名: tert-butyl N-[(Z)-1-pyridin-4-ylethylideneamino]carbamate
• CAS: 944882-27-3
• 化学式: C₁₂H₁₇N₃O₂
• 分子量: 235.286
• InChiKey: HLHZSASRXZTLLG-ZROIWOOFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-((1Z)-1-aza-2-(4-pyridyl)prop-1-enyl)(tert-butoxy)-carboxamide 在 4-二甲氨基吡啶 、 palladium on activated charcoal 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 24.0h， 生成 (+/-)-7-chloro-4-hydroxy-2-(4-pyridylethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione methanesulfonate
  参考文献：
  名称：

  Pyridazinoquinolinetriones as NMDA Glycine-Site Antagonists with Oral Antinociceptive Activity in a Model of Neuropathic Pain

  摘要：

  A series of 7-chloro-2,3-dihydro-2-[1-(pyridinyl)alkyl]-pyridazino[4,5-b]quinoline-1,4,10(5H)-triones were synthesized and found to have potent activity at the glycine site of the NMDA receptor. In some cases, these compounds possessed poor aqueous solubility that may have contributed to poor rat oral bioavailability. Subsequently, compounds have been identified with improved aqueous solubility and oral bioavailability. Several of these compounds were examined in a rat chronic constrictive injury (CCI) model of neuropathic pain and found to have potent activity when dosed orally.

  DOI：

  10.1021/jm060212s
• 作为产物：
  描述：

  4-乙酰吡啶 、 肼基甲酸叔丁酯 在 盐酸 作用下， 以 四氢呋喃 为溶剂， 以100%的产率得到N-((1Z)-1-aza-2-(4-pyridyl)prop-1-enyl)(tert-butoxy)-carboxamide
  参考文献：
  名称：

  Pyridazinoquinolinetriones as NMDA Glycine-Site Antagonists with Oral Antinociceptive Activity in a Model of Neuropathic Pain

  摘要：

  A series of 7-chloro-2,3-dihydro-2-[1-(pyridinyl)alkyl]-pyridazino[4,5-b]quinoline-1,4,10(5H)-triones were synthesized and found to have potent activity at the glycine site of the NMDA receptor. In some cases, these compounds possessed poor aqueous solubility that may have contributed to poor rat oral bioavailability. Subsequently, compounds have been identified with improved aqueous solubility and oral bioavailability. Several of these compounds were examined in a rat chronic constrictive injury (CCI) model of neuropathic pain and found to have potent activity when dosed orally.

  DOI：

  10.1021/jm060212s

文献信息

• Pyridazinoquinolinetriones as NMDA Glycine-Site Antagonists with Oral Antinociceptive Activity in a Model of Neuropathic Pain
  作者：Thomas M. Bare、Dean G. Brown、Carey L. Horchler、Megan Murphy、Rebecca A. Urbanek、Vernon Alford、Christine Barlaam、Martin C. Dyroff、James B. Empfield、Janet M. Forst、Keith J. Herzog、Richard A. Keith、Alan S. Kirschner、Chi-Ming C. Lee、Joseph Lewis、Frances M. McLaren、Kathy L. Neilson、Gary B. Steelman、Shephali Trivedi、Edward P. Vacek、Wenhua Xiao

  DOI：10.1021/jm060212s

  日期：2007.6.1

  A series of 7-chloro-2,3-dihydro-2-[1-(pyridinyl)alkyl]-pyridazino[4,5-b]quinoline-1,4,10(5H)-triones were synthesized and found to have potent activity at the glycine site of the NMDA receptor. In some cases, these compounds possessed poor aqueous solubility that may have contributed to poor rat oral bioavailability. Subsequently, compounds have been identified with improved aqueous solubility and oral bioavailability. Several of these compounds were examined in a rat chronic constrictive injury (CCI) model of neuropathic pain and found to have potent activity when dosed orally.